spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

IONTAS announces a new collaboration to identify novel immunotherapy targets

IONTAS

Antibody discovery agreement will support development of new therapeutics for acute and chronic inflammatory syndromes

Cambridge, UK, 07 May 2020: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, today announced it has entered into a collaboration agreement with Inotrem, a specialist in immunotherapy for acute and chronic inflammatory syndromes. As part of the agreement, IONTAS will apply its Mammalian Display technology to identify antibodies involved in the TREM-1 pathway.

TREM-1, an immunoreceptor expressed on innate immune cells, has been identified by Inotrem as a key therapeutic target for many acute or chronic inflammation syndromes, including sepsis and myocardial infarction. Under the terms of the collaboration, Inotrem will have access to IONTAS’ proprietary Mammalian Display platform, enabling specific high-affinity antibodies with optimal biophysical properties to be selected, to support the Company in developing TREM-1 inhibition-based therapies more efficiently, with reduced Chemistry, Manufacturing and Control (CMC) risk.

IONTAS’ Mammalian Display technology facilitates an increase in the probability and speed of antibodies successfully progressing into cell line development and manufacture. The platform screens antibodies in IgG format, in context of a mammalian cell, allowing researchers to assess lead candidate function, expression and developability early in the discovery process. In addition, large numbers of clones can be screened using fluorescence-activated cell sorting (FACS), in comparison to a low-throughput ELISA.

Dr Neil Butt, Chief Business Officer of IONTAS, said: “By harnessing our expertise and novel Mammalian Display technology, we are pleased to support Inotrem in its mission to leverage the therapeutic potential of the TREM-1 pathway. As well as generating an abundance of therapeutic antibody leads, our platform addresses developability issues early, to provide Inotrem with an increased likelihood of successfully identifying and progressing leads.”

Dr Marc Derive, Co-Founder and Chief Scientific Officer of Inotrem, commented:“Following the expansion of our Series B fundraising to €58million, this collaboration with IONTAS allows us to diversify our lead generation process, ultimately helping us to bring new therapies for major public inflammatory diseases.”

For further information, please visit: https://www.iontas.co.uk/technologies/
email admin@iontas.co.uk
web https://www.iontas.co.uk/
email Unit 2, Iconix Park, London Road, Pampisford, Cambridgeshire CB22 3EG
 
Print this page
Send to a friend
   
spacer
News and Press Releases

First cellularized collagen membrane implant to regenerate heart tissue in patients with ischemic heart disease

• 3P Biopharmaceuticals and Viscofan go ahead with this innovative project of regenerative medicine for cardiac use • Beginning of Phase I clinical trial in a group of 10 patients
More info >>


White Papers

Comparator Sourcing in Oncology Trials

Clinical Services International

This is an exciting time for oncology trials, year on year record numbers of therapeutics are launched and the indications for many drugs on the market are increasing rapidly. Immunotherapies and next generation biotherapeutics are being approved for more tumour types and a growing percentage of the late stage oncology pipeline are targeted biologics.
More info >>

Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement